Evaluation of cellular determinants required for in vitro xenotropic murine leukemia virus-related virus entry into human prostate cancer and noncancerous cells.
The newly identified retrovirus-the xenotropic murine leukemia virus-related virus (XMRV)-has recently been shown to be strongly associated with familial prostate cancer in humans (A. Urisman et al., PLoS Pathog. 2:e25, 2006). While that study showed evidence of XMRV infection exclusively in the prostatic stromal fibroblasts, a recent study found XMRV protein antigens mainly in malignant prostate epithelial cells (R. Schlaberg et al., Proc. Natl. Acad. Sci. U. S. A. 106:16351-16356, 2009). To help elucidate the mechanisms behind XMRV infection, we show that prostatic fibroblast cells express Xpr1, a known receptor of XMRV, but its expression is absent in other cell lines of the prostate (i.e., epithelial and stromal smooth muscle cells). We also show that certain amino acid residues located within the predicted extracellular loop (ECL3 and ECL4) sequences of Xpr1 are required for efficient XMRV entry. Although we found strong evidence to support XMRV infection of prostatic fibroblast cell lines via Xpr1, we learned that XMRV was indeed capable of infecting cells that did not necessarily express Xpr1, such as those of the prostatic epithelial and smooth muscle origins. Further studies suggest that the expression of Xpr1 and certain genotypes of the RNASEL gene, which could restrict XMRV infection, may play important roles in defining XMRV tropisms in certain cell types. Collectively, our data reveal important cellular determinants required for XMRV entry into different human prostate cells in vitro, which may provide important insights into the possible role of XMRV as an etiologic agent in human prostate cancer.
Bhosle
Sushma
S
Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA.
Suppiah
Suganthi
S
Molinaro
Ross
R
Liang
Yuying
Y
Arnold
Rebecca
R
Diehl
William
W
Makarova
Natalia
N
Blackwell
Jerry
J
Petros
John
J
Liotta
Dennis
D
Hunter
Eric
E
Ly
Hinh
H
D002460:Cell Line; D002478:Cells, Cultured; D004722:Endoribonucleases / Q000235:genetics / Q000378:metabolism*; D004847:Epithelial Cells / Q000821:virology; D005347:Fibroblasts / Q000821:virology; D017988:Gammaretrovirus / Q000502:physiology*; D054884:Host-Pathogen Interactions; D006801:Humans; D009052:Leukemia Virus, Murine; D008297:Male; D032389:Myocytes, Smooth Muscle / Q000821:virology; D011467:Prostate / Q000821:virology*; D011471:Prostatic Neoplasms / Q000821:virology*; D043562:Receptors, G-Protein-Coupled / Q000235:genetics / Q000378:metabolism*; D011991:Receptors, Virus / Q000235:genetics / Q000378:metabolism*; D056189:Viral Tropism; D053586:Virus Internalization; D000089842:Xenotropic and Polytropic Retrovirus Receptor
D043562:Receptors, G-Protein-Coupled; D011991:Receptors, Virus; C000715267:XPR1 protein, human; D000089842:Xenotropic and Polytropic Retrovirus Receptor; D004722:Endoribonucleases; C031956:2-5A-dependent ribonuclease
Gene Ther. 2000 Jun;7(11):910-3
10849549
PLoS One. 2010 Apr 01;5(4):e9948
20376347
Virology. 2010 Mar 30;399(1):23-30
20110097
J Virol. 1999 Nov;73(11):9362-8
10516044
Cancer Res. 2006 Apr 1;66(7):3531-40
16585177
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12386-90
12218182
J Virol. 2007 Oct;81(19):10550-7
17634227
Br J Cancer. 2005 Mar 28;92(6):1159-64
15714208
Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):927-32
9927670
Am J Hum Genet. 2002 Oct;71(4):981-4
12145743
Ciba Found Symp. 1987;125:3-25
2435471
Cell. 1993 Mar 12;72(5):753-65
7680958
Proc Natl Acad Sci U S A. 1978 Jan;75(1):256-60
272640
Nat Genet. 1999 Feb;21(2):216-9
9988277
Cancer Res. 2005 Aug 1;65(15):6651-9
16061645
Clin Prostate Cancer. 2003 Dec;2(3):177-80
15040862
Clin Cancer Res. 2004 Nov 1;10(21):7150-6
15534086
Biochim Biophys Acta. 2009 Apr;1792(4):289-96
19264126
Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1385-90
9990033
J Virol. 2004 Jun;78(11):5670-8
15140964
Urology. 2010 Apr;75(4):755-61
20371060
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16351-6
19805305
Virology. 1983 May;127(1):134-48
6305011
J Virol. 2010 Jun;84(11):5719-29
20335265
Retrovirology. 2005 Dec 15;2:76
16354307
Cancer Res. 2004 Dec 15;64(24):9144-51
15604285
PLoS Pathog. 2006 Mar;2(3):e25
16609730
Methods Mol Biol. 2003;229:43-55
12824620
Retrovirology. 2007 Oct 11;4:73
17931409
Nat Genet. 2002 Feb;30(2):181-4
11799394
Cancer Res. 2003 Oct 15;63(20):6795-801
14583476
Clin Cancer Res. 2006 Oct 1;12(19):5713-9
17020975
Am J Hum Genet. 2002 May;70(5):1299-304
11941539
N Engl J Med. 2003 Jul 24;349(4):366-81
12878745
J Biol Chem. 1995 Feb 24;270(8):4133-7
7876164
Infect Genet Evol. 2008 May;8(3):297-301
18295551
Cancer Invest. 1991;9(3):295-304
1913232
Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1655-60
17234809
J Virol. 2009 Jul;83(14):6995-7003
19403677
Int J Cancer. 2009 Jan 1;124(1):95-102
18844214
Science. 2009 Oct 23;326(5952):585-9
19815723
EMBO J. 1997 Nov 3;16(21):6355-63
9351818
Retrovirology. 2009 Oct 07;6:87
19811656
J Virol. 2009 Jul;83(14):7353-6
19403664
Virology. 2010 Feb 5;397(1):1-6
19959199
Cancer Res. 2008 Dec 1;68(23):9996-10003
19047182
Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2137-44
19567509
Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5166-71
20194752
Nat Genet. 2002 Dec;32(4):581-3
12415269
J Virol. 2008 Oct;82(20):9964-77
18684813